LATEST

EpiPen discounts offered after pricing flapAfter protests by patients, parents and Congressional representatives, Mylan said it would offer discounts on its epinephrine EpiPen Auto-Injector treatment to stop allergic reactions.
Game-changing depression drug on horizon
Game-changing depression drug on horizonFDA recently granted Breakthrough Therapy Designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide.
Are PCSK9 inhibitors too pricey?
Are PCSK9 inhibitors too pricey?PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.
New drug approved for chemotherapy nauseaFDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.
PBM giants pare down drug expenses
PBM giants pare down drug expensesWhen Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.
Medicare drug pricing debate heats upA senator is investigating whether Medicare's prescription drug benefit is vulnerable to manipulation by pharmaceutical companies after an exclusive Associated Press report showed that Medicare’s spending on certain drugs soared by 85 percent.
Wide geographic differences exist in treating diabetesA large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.
Overtreating glucose levels can take a toll on diabetes patientsMayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets.
FDA: Antibiotics class must carry warningFDA added new safety labeling changes for a class of antibiotics, fluoroquinolones (Levaquin, Cipro and other branded drugs), to enhance warnings about their association with disabling and potentially permanent side effects. Plus, the new labeling says that the drugs’ use should be limited in patients with less serious bacterial infections.
New diabetes drug up against leading brandsFDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).

Poll

View Results